Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content
| Autor: | Vincenzo Altieri, Giuseppe Di Lorenzo, Sabino De Placido, Antonio Giordano, Claudia Mazzarella, Matteo Ferro, Vincenzo Macchia, Angela Mariano, Daniela Terracciano, Angelina Di Carlo |
|---|---|
| Přispěvatelé: | Terracciano, Daniela, Mazzarella, C., Di Carlo, A., Mariano, A., Ferro, Matteo, Di Lorenzo, G., Giordano, A., Altieri, Vincenzo, DE PLACIDO, Sabino, Macchia, V. |
| Rok vydání: | 2010 |
| Předmět: |
Male
PCA3 Cancer Research medicine.medical_specialty Antineoplastic Agents Hormonal Receptor ErbB-2 medicine.drug_class Drug Evaluation Preclinical Prostate cancer Cytosol Cell Line Tumor Internal medicine PC3 NSE GW2974 ErbB1 ErbB2 Biomarkers Tumor medicine Humans Osteopontin Cell Proliferation Oncogene biology Cell growth Carcinoma Prostatic Neoplasms Chromogranin A Cancer General Medicine medicine.disease Androgen ErbB Receptors Endocrinology Oncology Drug Resistance Neoplasm Androgens Quinazolines biology.protein Carrier Proteins |
| Zdroj: | Oncology Reports. 24 |
| ISSN: | 1791-2431 1021-335X |
| DOI: | 10.3892/or_00000848 |
| Popis: | Prostate cancer is one of the most frequently diagnosed cancer in men. Treatment by radical prostatectomy, radiotherapy and anti-androgen drugs is successful in patients with localized cancer. However, prolonged androgen deprivation often leads to hormone refractory condition, associated with disease relapse. ErbB1 and ErbB2 activity has been correlated with androgen-independence. We determined the effects of GW2974, a dual inhibitor of ErbB-1 and ErbB-2 tyrosine kinase activity, on growth, NSE, chromogranin A and osteopontin cytosol content in the androgen-independent prostate cancer cell line PC-3. We found that PC-3 cell growth was inhibited by GW2974, whereas NSE and chromogranin A cell contents were stimulated and osteopontin cytosol level was not affected. The present data may have clinical implications for the treatment of advanced prostate cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|